{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-23-000065","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2023-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.720130+00:00","generated_at":"2026-06-09T18:35:10.216292+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Elicio Therapeutics announces departure of Chief Business Officer Annette Matthies effective Oct 19, 2023","bullets":["Annette Matthies, Ph.D. ceased as Chief Business Officer; separation agreement signed October 19, 2023.","Company will pay six months of base salary and reimburse COBRA premiums for up to six months.","Separation includes standard release of claims and confidentiality covenants.","No replacement or successor has been named; reason for departure not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-23-000065","json":"https://secwatch.observer/filing/0001601485-23-000065.json","markdown":"https://secwatch.observer/filing/0001601485-23-000065.md","text":"https://secwatch.observer/filing/0001601485-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000065/0001601485-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000065/angn-20231019.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T18:35:10.216292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba88cd9211","claim":"Annette Matthies departed as Chief Business Officer at Elicio Therapeutics, Inc..","evidence_excerpt":"On October 19, 2023 , Elicio Therapeutics, Inc. (the “Company”) and Annette Matthies, Ph.D., former Chief Business Officer of the Company, entered into a Separation and Release Agreement","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000065/0001601485-23-000065-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}